Abstract
Introduction
Combination products are a lifeline in today' s pharmaceutical industry, but
not all are created equal. Many companies use combinations late in the product
life cycle to extend patent life or to maximize revenues, but more-successful
combination product development addresses a market' s unmet need. Therefore,
not all potential combination products will have equal value. We asked
Decision Resources analysts to share their insights on combination products in
various disease markets and integrated these insights into our analysis of the
combination product market in this Spectrum Special Report.
Get the Answers You Need to Shape Your Strategy
- Several fi xed-dose combinations were blockbusters in 2006 while others
languished. Why do combination products fare well in some markets and not in
others? Why do similar products for similar indications fare very differently
in the market?
- Successful combinations are sometimes a result of a single company
combining its blockbuster agents, but several intercompany collaborations on
combination products have proved very successful. Which partnerships have been
most successful and why? Which markets are best suited to further intercompany
development?
- Combination products are becoming increasingly useful in product
life-cycle management. Which combination products are in development? What do
the experts think of their chances for success?
Scope
- Trends in Combination Products: Synergistic partnerships that tap unmet
needs in disease markets.
- Emerging Combinations in Select Markets: Cardiovascular, respiratory,
diabetes, pain.
- Select Companies with Fixed Combination Blockbusters: Abbott, AstraZeneca,
Boehringer Ingelheim, Gilead, GlaxoSmithKline, Johnson & Johnson, Merck,
Novartis, Schering-Plough.
- Challenges: Incorporating the untapped opportunity of biologics into
combination product development.
- Expert Commentaries: Insights from Decision Resources analysts,
consultants, and directors.
View Cart
